Pasithea Therapeutics closed at $0.53 on Nov 4, unchanged, 63.9% below its 52-week closing high. Volume of 2.3M shares was 1.66× its 20-day average (above normal).
Split-adjusted performance: +18.6% over one month, -37.6% over six months, -35.0% over one year.
Short interest was 174.6K shares at the Oct 15 settlement, up 9.2% from the prior report (0.5% of float, 1.6 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| KTTAPasithea Therapeutics | $0.5300 | 0.00% | −37.6% | — | — | — | $17.7M | |
| ALLRAllarity Therapeutics | $1.08 | −4.42% | −27.0% | — | — | — | $17.2M | Compare |
| MRKRMarker Therapeutics | $1.01 | +2.76% | −30.8% | — | — | — | $16.8M | Compare |
| CNTXContext Therapeutics | $0.2035 | +4.90% | −91.6% | — | — | — | $18.7M | Compare |
| MTEXMannatech | $8.64 | −0.06% | +77.0% | +3.8% | 3.8% | — | $16.7M | Compare |
| NEUPNeuphoria Therapeutics | $2.98 | −0.33% | −44.6% | — | — | — | $16.1M | Compare |
| COCPCocrystal Pharma | $1.01 | −5.61% | −28.4% | — | −3013.3% | — | $19.5M | Compare |
| KYNBKyntra Bio | $3.96 | −8.12% | −44.4% | — | — | — | $16.0M | Compare |
| IGCIGC Pharma | $0.1950 | +4.84% | −38.7% | −19.2% | −1107.9% | — | $20.2M | Compare |
No recent articles focused on Pasithea Therapeutics. 1 articles mention it in passing.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
